USA—Vesselon, Inc., a developer of patentable therapeutic co-formulations using an FDA-approved, biophysically activated lipid microsphere and self-assembling liposomes, has appointed Dr. Parviz Ghahramani as Senior Executive Vice President, Head of Research and Development, starting March 5.

With over 27 years of experience in clinical pharmacology, pharmacokinetics, modeling & simulation, and early drug development, Ghahramani brings a wealth of expertise to his new role.

Ghahramani will lead Vesselon’s clinical research and product development, with a main focus on driving commercialization strategies for the biotech firm, while also continuing his role as founder of Inncelerex, a multi-faceted Drug Development Consultancy company.

Ghahramani has held key leadership and strategic positions with leading pharmaceutical firms such as Pfizer, Roche, AstraZeneca, and Allergan (formerly Forest Laboratories).

His efforts have been critical in steering over 86 therapeutic development initiatives at various stages, including small compounds, biologics, and antibodies.

Ghahramani and his team at Inncelerex will contribute to the Vesselon platform’s development.

Ghahramani has had a substantial industry effect, as evidenced by his involvement in 31 New Drug Applications (NDA), Marketing Authorization Applications (MAA), and Japanese New Drug Applications.

He has been at the pioneering of regulatory meetings, including discussions with Advisory Committees and the creation of briefing booklets, particularly in the areas of Clinical Pharmacology and Modeling and Simulation.

His diverse experience includes oncology, CNS, anti-infectives, drug-device combinations, diabetic, GI, and respiratory treatments.

Ghahramani has been a driving force behind over 308 license and purchase assessments, as well as firm mergers, demonstrating his strategic vision and commercial ability.

Aside from his entrepreneurial achievements, Ghahramani has actively contributed to the scholarly community by publishing over 130 papers in prestigious international journals.

He has served as an advisor for organizations that contribute to the pharmaceutical landscape, including the European Society for Translational Medicine (ESTM) and the International Drug Discovery Science and Technology.

His position as a Professor at the University of Maryland demonstrates his dedication to giving back to the profession.

Dr. Parviz Ghahramani has a Ph.D. in Clinical Pharmacology, Pharm.D., M.Sc. in Statistics, and an MBA.

Clayton Larsen, President and CEO of Vesselon, welcomed Parviz and highlighted that his successful career in the sector has provided him with extensive expertise and experience in drug development, making him an excellent option to oversee their R&D efforts.

He went on to note that his track record of bringing innovative solutions to market while navigating the challenges of the drug research and regulatory landscape strengthens his position as Vesselon’s strategic leader.

Ghahramani on his part noted that the Vesselon platform has the potential to alter the pharmacokinetics of several drug classes, and that he is excited to introduce this new field of pharmacology to the clinic and then quickly into mainstream practice.

Vesselon has pioneered a transformational co-formulation process that greatly improves therapeutic bioavailability while developing new patentable entities for each drug without changing the active component.

 Using its Imagent lipid microspheres, which were originally FDA-approved for contrast ultrasound, Vesselon’s TriForm co-formulation wraps pharmaceuticals in gas microspheres while also producing drug-encapsulated self-assembling liposomes in the vial at the bedside.

This enables for selective and focal activation of the drug at and inside the tumour, considerably increasing the anti-tumour activity at the intended spot. 

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.